8-K: Bausch Health Completes DURECT Acquisition

Bausch Health Companies Inc. announced the successful completion of its tender offer and subsequent merger with DURECT Corporation.

Summary

• Bausch Health Companies Inc. (BHC) has successfully completed its acquisition of DURECT Corporation (DURECT).
• The transaction involved a tender offer to purchase all outstanding shares of DURECT common stock for $1.75 per share in cash.
• In addition to the cash payment, DURECT shareholders received one non-transferrable contingent value right (CVR) for each share.
• These CVRs represent the contractual right to receive a pro rata portion of two milestone payments, totaling up to $350,000,000 in aggregate, contingent upon the achievement of specific net sales milestones (net of retention bonuses).
• The tender offer and related withdrawal rights expired on September 10, 2025, at 5:00 p.m., New York City time.
• As of the expiration time, 19,984,767 DURECT shares were validly tendered and not withdrawn, representing approximately 62% of the total shares outstanding.
• All conditions of the offer, including the Minimum Condition, were satisfied.
• On September 11, 2025, BHC Lyon Merger Sub, Inc., a wholly-owned subsidiary of Bausch Health Americas, Inc. (BHA) and an indirect subsidiary of BHC, accepted all validly tendered shares for payment.
• Following the tender offer, BHC Lyon merged with and into DURECT on September 11, 2025, under Section 251(h) of the General Corporation Law of the State of Delaware, without a vote of DURECT's stockholders.
• DURECT continues as the surviving corporation and is now a wholly-owned subsidiary of BHA, operating under the name DURECT Corporation.

Sentiment

Score: 7

Explanation: The filing confirms the successful and expected completion of the DURECT acquisition, a strategic move for Bausch Health. While no new financial performance data is provided, the successful execution of the tender offer and merger is a positive for BHC's strategic objectives.

Positives

• The successful completion of the tender offer and merger fulfills a previously announced strategic objective for Bausch Health.
• The acquisition was completed efficiently under Section 251(h) of the DGCL, without requiring a separate DURECT stockholder vote.

Risks

• The full value realization for former DURECT shareholders from the contingent value rights (CVRs) is dependent on the achievement of specific net sales milestones, which are not guaranteed.

Future Outlook

The filing primarily reports the completion of a past event. The only forward-looking aspect relates to the potential for future CVR payments, which are contingent on DURECT's product net sales milestones.

Industry Context

This acquisition represents a consolidation within the pharmaceutical or healthcare sector, where larger companies like Bausch Health acquire smaller, specialized firms like DURECT to expand their product pipelines or market share. Such transactions are common strategies for growth and diversification in the industry.

Comparison to Industry Standards

• This 8-K is a factual report on the completion of an acquisition and does not provide financial performance metrics or operational results that would allow for a direct comparison to industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders (BHC): The acquisition is expected to contribute to BHC's long-term growth and strategic objectives by expanding its product portfolio.
• Shareholders (DURECT): Received $1.75 cash per share plus a CVR, providing immediate liquidity and potential future upside based on product performance.
• Employees (DURECT): Retention bonuses are mentioned in relation to CVR milestone achievements, indicating efforts to retain key personnel.
• Customers: Potential for new or enhanced product offerings from the combined entity.

Next Steps

• Integration of DURECT Corporation into Bausch Health Americas, Inc.
• Potential future payments to former DURECT shareholders upon achievement of net sales milestones for the CVRs.

Key Dates

Recommendation

The 8-K filing confirms the successful completion of the DURECT acquisition, an event that was previously announced and expected. This is a positive for Bausch Health's strategic execution and portfolio expansion. However, the filing does not contain new financial results or forward-looking guidance beyond the CVR structure that would significantly alter the investment thesis for BHC based solely on this announcement. Investors would likely maintain their current position while awaiting further financial updates on the integration and performance of the acquired assets.

Keywords

Bausch Health, DURECT, acquisition, merger, tender offer, contingent value right, CVR, pharmaceutical, healthcare, BHC, BHA